Eupraxia Pharmaceuticals (NASDAQ:EPRX) Price Target Raised to $16.00

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Free Report) had its price target increased by HC Wainwright from $11.00 to $16.00 in a research note released on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.23) EPS, FY2029 earnings at ($0.96) EPS and FY2030 earnings at $0.14 EPS.

EPRX has been the subject of several other research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 8th. Oppenheimer restated an “outperform” rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, October 20th. Wall Street Zen lowered shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Sunday, November 8th. Wedbush initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, September 24th. They set an “outperform” rating and a $17.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Get Our Latest Analysis on EPRX

Eupraxia Pharmaceuticals Trading Up 4.4%

Eupraxia Pharmaceuticals stock opened at $8.15 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 12.25 and a quick ratio of 16.00. Eupraxia Pharmaceuticals has a 52 week low of $5.63 and a 52 week high of $9.32. The stock has a fifty day moving average of $7.64 and a 200-day moving average of $7.24.

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.03. Equities research analysts forecast that Eupraxia Pharmaceuticals will post -0.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of EPRX. Persistent Asset Partners Ltd acquired a new position in Eupraxia Pharmaceuticals in the 2nd quarter worth about $25,000. BlackRock Inc. acquired a new stake in shares of Eupraxia Pharmaceuticals during the second quarter valued at about $40,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Eupraxia Pharmaceuticals by 28.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock valued at $133,000 after purchasing an additional 3,500 shares in the last quarter. AXQ Capital LP grew its holdings in shares of Eupraxia Pharmaceuticals by 34.2% during the second quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock worth $140,000 after purchasing an additional 5,390 shares during the last quarter. Finally, Ingalls & Snyder LLC grew its holdings in shares of Eupraxia Pharmaceuticals by 10.2% during the third quarter. Ingalls & Snyder LLC now owns 75,450 shares of the company’s stock worth $687,000 after purchasing an additional 7,000 shares during the last quarter.

Key Headlines Impacting Eupraxia Pharmaceuticals

These are some of the EPRX headlines that stood out recently:

  • Positive Sentiment: Cantor Fitzgerald and Oppenheimer each initiated or reiterated a Buy view on EPRX, adding to positive analyst coverage. Cantor Fitzgerald Buy rating Oppenheimer Buy rating
  • Neutral Sentiment: Interim results from Eupraxia’s Phase 2b eosinophilic esophagitis (EoE) trial are expected in December, creating a key upcoming clinical catalyst. Q3 results and trial update timing
  • Negative Sentiment: HC Wainwright lowered its fiscal 2027 and 2029 EPS forecasts, while the company reported a wider third-quarter loss—risks that temper the positive analyst news. Analyst estimates Quarterly loss report

About Eupraxia Pharmaceuticals

(Get Free Report)

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.

Further Reading

Analyst Recommendations for Eupraxia Pharmaceuticals (NASDAQ:EPRX)

Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.